Table 2.
Univariate analysis for baseline biomarkers for progression-free survival in (a) 96 mCRPC-patients prior to Abiraterone therapy and (b) in 17 patients with a baseline NLR >5 after eight weeks of therapy.
| (a) Univariate Analysis PFS at Baseline | (b) Univariate Analysis of PFS in n = 17 Patients with Baseline NLR > 5 after Eight Weeks of Abiraterone | ||||
|---|---|---|---|---|---|
| Variable | HR (95%CI) | p | Variable | HR (95%CI) | p |
| ECOG | <0.01 | ECOG | 0.57 | ||
| 0–1 | 1 (reference) | 0–1 | 1 (reference) | ||
| 2 | 2.9 (1.7–4.9) | 2 | 1.4 (0.4–4.8) | ||
| LDH baseline >UNL | <0.01 | LDH baseline >UNL | 1 (reference) | 0.52 | |
| No | 1 (reference) | No | |||
| Yes | 2.6 (1.6–4.3) | Yes | 2.0 (0.3–15.4) | ||
| Visceral metastases | 0.02 | Visceral metastases | 0.85 | ||
| No | 1 (reference) | No | 1 (reference) | ||
| Yes | 2.2 (1.4–3.5) | Yes | 0.9 (0.2–3.3) | ||
| ALP baseline >UNL | 0.13 | ALP baseline >UNL | 0.55 | ||
| No | 1 (reference) | No | 1 (reference) | ||
| Yes | 1.4 (0.9–2.1) | Yes | 1.4 (0.5–3.9) | ||
| NLR | 0.11 | NLR | 0.04 | ||
| <5 | 1 (reference) | No change | 1 (reference) | ||
| >5 | 1.6 (0.9–2.8) | Change to <5 | 4.1 (1.1–15.8) | ||
| Abiraterone | 0.10 | PSA decline ≥50% | 0.14 | ||
| Pre-Docetaxel | 1 (reference) | Yes | 1 (reference) | ||
| Post-Docetaxel | 1.4 (0.9–2.2) | No | 2.7 (0.7–10.2) | ||
| Gleason Score | 0.10 | Abiraterone | 0.41 | ||
| <8 | 1 (reference) | Pre-Docetaxel | 1 (reference) | ||
| ≥8 | 1.5 (0.9–2.3) | Post-Docetaxel | 1.6 (0.5–4.6) | ||
| Lymphonodal metastases | 0.77 | Gleason Score | 0.63 | ||
| No | 1 (reference) | <8 | 1 (reference) | ||
| Yes | 0.9 (0.6–1.5) | ≥8 | 1.3 (0.4–3.9) | ||
| Bone Metastases | 0.82 | Lymphonodal metastases | 0.41 | ||
| No | 1 (reference) | No | 1 (reference) | ||
| Yes | 1.1 (0.5–2.2) | Yes | 0.6 (0.2–1.9) | ||
Abbreviations: PFS: progression free survival; HR: hazard ratio; 95%CI: 95% confidence interval; ECOG: Eastern Collaborative Oncology Group; LDH: lactate dehydrogenase; UNL: upper normal limit; PSA: prostate-specific antigen; NLR: neutrophil-to-lymphocyte ratio; ALP: alkaline phosphatase; OS: overall survival.